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Abstract
Currently there are a dozen or so of new vaccine candidates in clinical trials for prevention of
tuberculosis (TB) and each formulation attempts to elicit protection by enhancement of cell-
mediated immunity (CMI). In contrast, most approved vaccines against other bacterial path-
ogens are believed to mediate protection by eliciting antibody responses. However, it has
been difficult to apply this formula to TB because of the difficulty in reliably eliciting protective
antibodies. Here, we developed capsular polysaccharide conjugates by linking mycobacte-
rial capsular arabinomannan (AM) to either Mtb Ag85b or B. anthracis protective antigen
(PA). Further, we studied their immunogenicity by ELISA and AM glycan microarrays and
protection efficacy in mice. Immunization with either Abg85b-AM or PA-AM conjugates elic-
ited an AM-specific antibody response in mice. AM binding antibodies stimulated transcrip-
tional changes in Mtb. Sera from AM conjugate immunized mice reacted against a broad
spectrum of AM structural variants and specifically recognized arabinan fragments. Conju-
gate vaccine immunized mice infected with Mtb had lower bacterial numbers in lungs and
spleen, and lived longer than control mice. These findings provide additional evidence that
humoral immunity can contribute to protection against Mtb.
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Author summary
Vaccine design in the TB field has been driven by the imperative of attempting to elicit
strong cell-mediated responses. However, in recent decades evidence has accumulated
that humoral immunity can protect against many intracellular pathogens through numer-
ous mechanisms. In this work, we demonstrate that immunization with mycobacterial
capsular arabinomannan (AM) conjugates elicited responses that contributed to protec-
tion against Mtb infection. We developed two different conjugates including capsular AM
linked to the Mtb related protein Ag85b or the Mtb unrelated PA from B. anthracis and
found that immunization with AM conjugates elicited antibody populations with different
specificities. These surface-specific antibodies could directly modify the transcriptional
profile and metabolism of mycobacteria. In addition, we observed a prolonged survival
and a reduction in bacterial numbers in lungs and spleen in mice immunized with Ag85b-
AM conjugates after infection with Mtb and that the presence of AM-binding antibodies
was associated with modest prolongation in survival and a marked reduction in mycobac-
terial dissemination. Finally, we show that AM is antigenically variable and could poten-
tially form the basis for a serological characterization of mycobacteria based on serotypes.
Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of TB, can establish latent or progressive
infection despite the presence of a fully functioning immune system. The capacity of Mtb to
avoid immune-mediated clearance reflects a necessary association with the human host that
has led to an evolved and coordinated program of immune evasion strategies, including inter-
ference with antigen presentation to prevent and/or alter the quality of T-cell responses [1].
There is strong evidence to suggest that the mycobacterial cell envelope is of key importance
for survival in the host [2]. The mycobacterial envelope consists of three major components:
the plasma membrane, the cell wall, and an outermost capsule [2]. Bacterial capsules are pro-
tective structures important for the interaction with and successful colonization of the host [3].
Toxic substances have recently been found in the mycobacterial capsule, suggesting the contri-
bution of this compartment to mycobacterial pathogenesis [4].
The mycobacterial capsule is loosely attached to the surface and is mainly composed of pro-
teins and polysaccharides [2]. The major surface exposed capsule polysaccharides are a 120
kDa glycogen-like α-glucan, a 15 kDa arabinomannan (AM) and a 4 kDa mannan [5]. Both
AM and mannan are structurally related to lipoarabinomannan (LAM), the major lipopolysac-
charide of the mycobacterial cell wall. LAM is also known for having biological effects during
its interaction with host cells, including immunosuppression of T cell responses or interfer-
ence with macrophage activation [6]. LAM and AM can each elicit high antibody responses in
infected hosts [7]. A low antibody to LAM response in children with TB was associated with
disseminated mycobacterial disease [8]. That report concluded that a weak antibody response
to LAM and other mycobacterial antigens increased the likelihood of dissemination [8]. Pre-
sumably, antibodies can also contribute to the host defense against Mtb by promoting the
clearance of LAM [9]. In fact, several reports on AM or LAM-binding monoclonal antibodies
have established their capacity to contribute to the clearance of mycobacteria from the host
[10, 11].
In 2014, there were an estimated 9.4 million new cases of TB and 1.5 million people died
from TB, including 1.1 million deaths among HIV-negative individuals and 0.4 million among
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people who were HIV-positive [12]. Efforts to control the disease include the development of
“point-of-care” tests, new TB drugs, the use of the Bacille Calmette-Guerin (BCG) vaccine and
the development of new vaccines. Most of the new vaccine candidates against TB that have
entered in clinical trials fall into one of the following groups: (I) live attenuated vaccines to
replace BCG; (II) subunit vaccines to be given after initial BCG vaccination [13]; and (III) sin-
gle immunodominant antigens, usually secreted, such as ESAT-6, Cfp10 and Ag85b along
with other adjuvants [13]. These vaccine candidates were developed with the working assump-
tion that immunity against TB relied solely on cellular defense mechanisms [14]. While there
is no doubt that cell-mediated immunity is a major arm in the control of mycobacterial infec-
tion, there are now compelling data that certain antibodies are active against mycobacteria [9–
11, 15].
In this study, we have generated two different polysaccharide conjugates made of capsular
Mtb AM and proteins Ag85b (Ag85b-AM) from Mtb H37Rv and protective antigen (PA)
(PA-AM) from Bacillus anthracis, aiming to create AM-specific humoral immunity prior to chal-
lenging mice with virulent mycobacteria via aerosol. Previous studies using similar approaches
have shown that secreted AM or delipidated LAM-containing conjugates provided some protec-
tion against Mtb infection in mice, rabbit or guinea pigs [15, 16]. Here we report that capsular
AM conjugates promote an AM-binding antibody response in mice that is associated with
reduced bacterial numbers in lungs and spleen, and prolonged survival in immunized mice. Our
study provides additional evidence for an important role for antibodies in protection against
Mtb and suggests that polysaccharide antigens could be useful components of future vaccines to
fight TB.
Results
Capsular arabinomannan conjugates
Mtb H37Rv was grown in minimal media without Tyloxapol, which is known to release cap-
sule [4]. After 14 d cultures were harvested and an aliquot was submitted to transmission elec-
tron microscopy (TEM) analysis to examine bacterial cells for the presence of the capsule. An
electron transparent zone was clearly visible surrounding Mtb cells (S1 Fig). Visualization of
Mtb cells under the scanning electron microscope revealed that the capsule is a matrix com-
posed of small spherical units of approximately 50 nm in diameter [17] (S1 Fig). Arabinoman-
nan (AM) is a low molecular weight polysaccharide that can be recovered from the upper
phase of a chloroform-methanol-water extraction step [18] and separated from the other low
molecular weight polysaccharides after proteinase K treatment by size exclusion chromatogra-
phy (S1 Fig). Three major peaks were obtained of molecular mass 20 kDa (peak a), 10 kDa
(peak b) and 4 kDa (peak c). According to the glycosyl composition analysis of the pooled
peaks, peak a consisted of two main glycosides, arabinose and mannose in a ratio (2:1). This
result is consistent with mycobacterial capsular AM and other reported analysis in mycobacte-
ria [5, 18]. In addition, only peak “a” showed binding to 9d8 an AM-specific monoclonal
antibody (Mab) and not to 24c5, recognizing α-glucan (S1 Fig). AM, as many other polysac-
charides are poorly immunogenic because they are T cell independent antigens; therefore,
immunization with polysaccharides generally does not elicit IgG immune responses. We
hypothesized that vaccine-induced AM antibodies had value in protecting against TB. For this,
we conjugated Mtb capsular AM, corresponding to the purify fraction (peak a) to different
protein carriers. We did not make conjugates to other fractions that did not correspond to
AM, as that was not the scope of this work. We selected Ag85b as Mtb-related protein carrier
to test whether inclusion of AM would boost its recognized protective properties as an immu-
nogen. In addition, we also linked Mtb capsular AM to the protective antigen (PA) from
Polysaccharide conjugate vaccine against Mycobacterium tuberculosis
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Bacillus anthracis as non-Mtb related antigen to set up a system where AM-binding immunity
could be evaluated in an exclusive way. We developed Ag85b-AM and PA-AM conjugates
using the cyanylating reagent CDAP as previously described [19, 20]. The conjugate products
were separated by size exclusion chromatography on a Sephacryl S-200 (GE healthcare) (S2
Fig) in PBS. Ag85b-AM and PA-AM conjugates showed a protein-polysaccharide molar ratio
of 1:8 and 1:7, respectively, as determined by Bradford and the phenol-sulphuric acid assays.
Antibody response of AM conjugates in mice
To test the immunological response of the different AM conjugates, mice were immunized
with different amounts of Ag85b-AM or PA-AM conjugates (1, 5 and 10 μg) in 1% Alum.
Alternatively, three different groups of mice received 1 μg of either Ag85b, PA or 10 μg of AM,
also in 1% Alum. Each mouse was boosted twice every two weeks and serum samples were
taken to determine the kinetics of specific antibodies (S3 Fig). No antibody response was
detected in PBS, AM or 1% Alum alone-immunized mice. We determined that immunization
with three doses of 10 ug of Ag85b-AM conjugate provided elevated levels of AM-specific Abs
(1:3000) (S3 Fig). We believe that our regime of immunization provided sufficient and stable
levels of Ag85b-specific T cells as it has been previously shown using similar immunization
approaches [21].
We further analysed the IgG subclasses and IgM in sera isolated at day 45 after initial
immunization (Fig 1A and 1B). Immunization with either Ag85b or PA induced high levels of
protein-specific antibodies (1:6000, 1:4000) and no polysaccharide-specific antibodies as
expected. Immunization with conjugates promoted an antibody response to both the protein
and polysaccharide components of the conjugates, being the response to proteins very similar
to that the immunization with protein alone. Ag85b-specific Ab response consisted on a mix
of all subclasses being IgG2c the most prevalent with a three fold increase relative to the other
groups. Immunization with PA alone induced a mix of IgM, IgG1 and IgG2c (Fig 1A and 1B).
The AM-binding antibody response was very similar between the two conjugates in terms of
diversity. A mix IgM, IgG1 and IgG2b was observed in AM-Ag85b immunized mice versus an
exclusive IgG2b in AM-PA immunized mice.
Since AM is a mycobacterial capsular polysaccharide we considered whether AM polyclonal
sera would recognize the outermost compartment of Mtb. However, any interpretation of the
data needs to take into account the fact that AM and LAM share epitopes, suggesting that AM-
immune serum might also label LAM. In fact, analysis of the specificity of AM-serum for bind-
ing to other Mtb cell wall components by ELISA revealed a cross reactivity with LAM, Man-
LAM and LM and absence of binding to arabinogalactan (AG), mycolyl-arabinogalactan-
peptidoglycan complex (mAGP) or trehalose deoxy mycolate (TDM) (S4 Fig). Notably, there
is no Ab available to distinguish between AM and LAM. To explore the location of Ab binding
we utilized immunogold TEM with AM-binding sera (Fig 1C and 1D and S5 Fig). We used
encapsulated Mtb cells that were generated by growing mycobacteria in the absence of deter-
gent. It is known that supplementation of the culture with detergent strips the mycobacterial
capsule [22]. Grids containing sections of Mtb cells were labelled without any primary anti-
body (NP) as controls and no immunogold was detected. Similarly, no labelling was observed
when the experiment was performed with a PA-binding serum, confirming the lack of cross
reactivity of PA-binding antibodies to Mtb. We observed labelling in all conditions where
AM-binding sera were used. The location of the immunogold particles in cells labelled with
Ag85b-AM serum was not restricted to the surface but distributed all over the bacterial cell
(Fig 1C). On the contrary, most of the immunogold labelling observed in grids treated with
AM-PA serum was restricted to the bacterial surface. Since both conjugates were generated
Polysaccharide conjugate vaccine against Mycobacterium tuberculosis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006250 March 9, 2017 4 / 28
Fig 1. Antibody response to conjugate immunization in mice. (A) Titers of AM (Mtb) (top graph) or Ag85b (bottom graph)-specific antibodies
measured by ELISA in serum from C57BL/6 mice (n = 3 per group) immunized with 10 μg of AM-Ag85b conjugate, 1 μg of Ag85b, 10 μg of AM or PBS.
Polysaccharide conjugate vaccine against Mycobacterium tuberculosis
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with the same AM molecule, surface labelling is most probably due to AM or LAM. However,
in the case of Ag85b-AM-immune serum, Abs to Ag85b could also be labelling this protein
throughout the mycobacterial cell, explaining the broad distribution of the labelling that we
observed.
When immunolabeling was performed on grids containing unencapsulated mycobacteria
(grown in the presence of detergent) we observed a reduction on labelling, indicating that
most of the material being recognized in encapsulated Mtb is not present in unencapsulated
Mtb (Fig 1C and 1D). These results indicate that immunization with AM-conjugates induces a
potent and specific antibody response primarily directed to the mycobacterial surface and spe-
cifically to the capsule.
Dissection of the AM-binding antibody response by glycan microarrays
AM is a neutral and heterogeneous capsular polysaccharide comprised of a mannan backbone
substituted by a branched arabinan, further modified by mannose residues at the non-reduc-
ing end [23]. To gain insight into the specific differences in serum reactivity provided by the
conjugates, we analyzed immune sera on glycan microarrays including 30 synthetic AM frag-
ments (Fig 2 and S6 Fig). The synthetic AM fragments included on the array are representative
of the motifs present in all three of these domains (S6 Fig). Selection of compounds for synthe-
sis was based on the reported structure of AM.
Further, AM-arrays were probed with diluted sera from either AM-PA or AM-Ag85b con-
jugate-immunized mice. PA and Ag85b-immunized mice and the AM-binding monoclonal
antibody (mAb) 9d8 were used as controls. We observed a more diverse repertoire of AM frag-
ment recognized by conjugate sera relative to the control mAb 9d8 (Fig 2A). This is consistent
with the response expected from a polyclonal serum versus a mAb. A reduced response was
detected in arrays probed with the PA or Ag85b-serum for the majority of the epitopes. Nota-
bly, we observed a common reactivity profile between sera from both conjugate-immunize
mice, indicating that the conjugated PS might have been modified similarly. More specifically,
we observed a prevalent recognition for epitopes ranging from linear arabinose fragments
including 4 to 8 sugar units (#24) to highly branched arabinose polysaccharides (#16, #17, #20,
#23 and #24). (Fig 2A and 2B). The highest reactivity in AM-PA serum was observed for frag-
ments 23, 24 and 22, whereas in AM-Ag85b serum was observed for fragments 16, 23, 24 and
20. All fragments represented linear or branched arabinose polysaccharides, except for frag-
ment 22, which included the arabinan core of fragment 14 but highly mannosylated (three
mannose residues) at both reducing ends. Fragments 5 and 6 were preferentially recognized by
the mAb 9d8 and included structures with a short-branched arabinan core manosylated at
both ends. Both conjugate sera shared reactivity of fragments 1, 10 and 12 with 9d8. These
fragments included short and linear arabinose glycans (#1), short and branched arabinan mol-
ecules with low mannosylation (#12) and xylose-substituted at the mannose reducing end
(#10). These results suggest that AM-binding antibody response is directed to a diverse set of
glycans, mostly associated to the arabinan core and that the protective mAb 9d8 reacts to a
reduced set of glycans including a less complex repertoire.
(B) Titers of AM (Mtb) (top graph) or PA (bottom graph)-specific antibodies measured by ELISA in serum from C57BL/6 mice (n = 3 per group)
immunized with 10 μg of AM-PA conjugate, 1 μg of PA, 10 μg of AM or PBS. The results are representative of three independent experiments
performed in the same manner. (C) Immunogold electron microscopy of thin sections of Mtb H37Rv cells treated with immune sera specific for the
indicated antigens and detected with a 6-nm IgG gold-labeled anti-mouse antibody. Immunolabeling was tested in Mtb grown in minimal medium with
(MM-T) and without tyloxapol (MM). Scale bars: 100 nm. (D) Quantitative analysis of the immunobeling of immune sera by determining the number of
gold particles per cell. Bars are mean +/- sem. NP, denotes No Primary antibody. **P < 0.01 using one-way ANOVA. Data are mean +/- sem. ns, not
significant.
https://doi.org/10.1371/journal.ppat.1006250.g001
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Fig 2. Assessment of the relative IgG-binding of AM immune sera the 29 printed AM fragments. (A) Heat map of AM glycan microarray data obtained
after incubation with pooled murine sera diluted 1:400 followed by labeled anti-IgG. Data are mean of three independent spots. Values are relative fluorescence
units. (B) AM fragments included in the glycan microarray representing the AM molecule recognized by the indicated serum. The numbers correspond to those
in A and S6 Fig.
https://doi.org/10.1371/journal.ppat.1006250.g002
Polysaccharide conjugate vaccine against Mycobacterium tuberculosis
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Transcriptional response of Mtb during AM-binding antibody interaction
Recently a new function for humoral immunity was described whereby the binding of specific
antibodies to microbes triggered transcriptional responses that were associated with physiolog-
ical changes [24, 25]. Consequently, we investigated whether capsular AM-binding antibodies
elicited transcriptional changes in Mtb by incubating encapsulated Mtb with AM-PA serum
for 4 h and comparing the changes in transcription with a condition including PA immune
serum using microarrays (Fig 3). Microarray data was deposited with the GEO NCBI database
with the accession number GSE77711.
We observed a consistent and significant upregulation of most of the mce1 operon (Fig
3A and 3B), consisting of 13 genes encoding a putative ABC lipid transport system special-
ized in mycolic acids [26]. Upregulation of the mce1 operon was also observed when Mtb is
inside host cells [27]. Moreover, an Mtb mutant defective in the mce1 operon was shown to
be hypervirulent in mice and produce more mycolic acids [28, 29]. The fact that umA, a
mycolic acid synthase, was downregulated lead us to hypothesize that upregulation of mce1
operon could result in a reduction in the mycolic acid content of Mtb cells upon interac-
tion with AM-binding immune serum. Indeed, when we measured fatty acids by TLC, we
observed reduction in alpha, keto and methoxy mycolic acids levels (Fig 3C), establishing
that antibody-induced transcriptional changes resulted in mycobacterial biochemistry
changes.
We also observed upregulation in some of the nuo genes, which are involved in aerobic res-
piration (Fig 3A). Of note, the gene encoding for isocytrate lyase (aceA, icl1), which is known
to be required for persistence in the mouse model, was downregulated in Mtb treated with
AM-binding serum. Similarly, transcript levels of cysD, which encode a sulfate adenylyltrans-
ferase involved in sulphate metabolism, were reduced in AM-treated Mtb (Fig 3A and 3B). We
could not explain why lipF, encoding a lipid esterase, appeared as downregulated in the micro-
array while this transcript showed a four-fold upregulation relative to untreated Mtb (Fig 3B).
These results indicate that antiserum including antibodies with specificities for Mtb capsular
AM can alter the lipid metabolism and the fitness of mycobacteria.
Protective efficacy of AM conjugates in mice
To separately test the ability of the two conjugates (Ag85b-AM and PA-AM) to modify the
course of Mtb infection, mice were immunized three times with 10 μg of each conjugate and
challenged with virulent tubercle bacilli by the respiratory route 4 weeks after the last immuni-
zation. Immunization controls included AM, PBS (1% Alum), and 1 x 106 BCG. At 4 weeks
after challenge mice were sacrificed and bacterial loads were assessed in lung and spleen (Fig
4A and 4B). As Ag85b is a well known immunogenic and protective Mtb antigen [30], we ini-
tially tested whether AM-Ag85b conjugate could control bacterial replication more efficiently
than Ag85b alone. An immunizing dose of Ag85b equivalent to that of included in the conjugate
was used to generate Ag85b-immunized mice. Both conjugate and Ag85b-immunized mice
showed similar reduction in mycobacterial numbers in the lung at 4 weeks (Fig 4A). Conversely,
we noticed a more significant reduction in bacterial counts in spleen in AM-Ag85b immunized
mice, similar to BCG-immunized mice (Fig 4B). Histological analysis revealed marked differ-
ences in tissue inflammation in mice immunized with AM, and adjuvant relative to those immu-
nized with AM-Ag85b and Ag85b mice (Fig 4C), with the latter groups manifesting more intact
lung morphology with less inflammation. We observed a major difference in the gross pathology
of lungs from the AM-Ag85b-immunized mice compared to Ag85b-immunized mice, as evident
by less diseased tissue. AM-Ag85b immunized mice showed a reduction in both the number of
infiltrates and the percentage of diseased tissue, although these differences were not significant
Polysaccharide conjugate vaccine against Mycobacterium tuberculosis
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Fig 3. Effect of AM immune serum on the transcriptional profile of M. tuberculosis. (A) Transcriptomic profile of Mtb during
treatment with AM-PA murine serum (1:400) compared to PA murine serum (1:400) for 4 h. The heat map shows transcriptional
changes from three biologically independent replicates labelled as A, B and C. (B) Expression ratio of the indicated Mtb genes
measured as the average relative expression of AM-PA serum vs PA serum-treated Mtb by quantitative real time PCR (qRT-PCR).
(*P < 0.05, **P<0.01 ***P < 0.001, one-way ANOVA with Tukey post-test). (C) Analysis of fatty acid methyl esters (FAMEs) and
mycolic acid methyl esters (MAMEs) in M. tuberculosis H37Rv labelled with 14C-acetate for 22h prior to treatment with the indicated
serum preparations for 5 h. Lipids were extracted and analyzed by TLC as described in Methods. The same amount of cpm was
spotted for each sample.
https://doi.org/10.1371/journal.ppat.1006250.g003
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Fig 4. Immunization with conjugates protect against Mtb infection. (A,B) Bacterial load (CFUs) in the lungs (A) and spleen (B) of
individual C57BL/6 mice, immunized with the indicated preparations was determined at 4 weeks after infection with a low dose of Mtb
H37Rv via aerosol (approx. 100 CFUs). The results are pooled values from two similar and independent experiments. Experimental
groups used 5 mice. (*P < 0.05, **P<0.01 ***P < 0.001, one-way ANOVA with Tukey post-test). (C) Representative H&E staining
images from lungs of C57BL/6 mice immunized with the indicated preparations and aerosol infected with Mtb H37Rv for 4 weeks. A
representative lung section for each treatment is shown. (D) Survival of mice immunized with PBS (n = 10), 1 × 106 CFU of BCG
(n = 10), 10 μg of AM (Mtb)-Ag85b (n = 10), 10 μg of AM (Mtb)-PA conjugate (n = 10) or 1 μg of Ag85b (n = 10) and challenged with
~100 CFU of aerosolized Mtb H37Rv. All the immunized mice were significantly different from that of PBS-treated mice (P < 0.001, log-
rank test for AM-Ag85b and BCG; P = 0.0064, log-rank test for Ag85b). No differences between the immunized groups were found
except for Ag85b vs AM-Ag85b immunized mice (P = 0.0166). The survival curve for AM(Mtb)-PA was significantly different from that
of PBS (P = 0.049, Gehan-Breslow-Wilcoxon test; P = 0.057, log-rank test). Survival studies were performed twice with similar results.
https://doi.org/10.1371/journal.ppat.1006250.g004
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(S7 Fig). Next, we tested for the ability of these conjugate to influence the survival of mice chal-
lenged with a low dose of virulent tubercle bacilli via aerosol (Fig 4D). As a positive control, we
included mice immunized with 1 x 106 BCG. All immunized mice, including BCG, Ag85b and
conjugate immunized mice significantly lived longer than the non-immunized mice injected
with adjuvant. No differences were observed between BCG and conjugate immunized mice.
Mice immunized with AM-Ag85b lived significantly longer than Ag85b immunized mice
(P = 0.0166) indicating that AM-binding antibodies contributed to prolonging the survival of
infected mice. These results suggested that antibodies to Ag85b were also protective and could
be masking any protective contribution of AM-binding immunity against Mtb whereas the lon-
ger survival in AM-Ag85b immunized mice suggested that AM-binding antibodies contributed
to protection. Consequently, we analyzed the protective efficacy of AM-PA conjugates to assess
the exclusive contribution of AM-binding immunity. Of note, a 0.42 log reduction (P = 0.04) in
lung CFUs was observed in mice immunized with AM-PA conjugates (Fig 4A). Immunization
with either AM and PA alone did not provide any protection and similar CFUs numbers as in
1% Alum-treated mice were counted in the lungs. When we analyzed bacterial loads in spleen
we observed a significant reduction in CFUs in AM-PA immunized mice, similar to AM-Ag85b
and BCG immunized mice, followed by Ag85b (Fig 4B). Consistent with the relatively weak abil-
ity of AM-PA conjugates to control bacterial replication in the lungs, we observed comparable
lung pathology to non-immunized or PA and adjuvant-immunized mice (Fig 4C). Although we
measured a mean of 5 infiltrates in lungs of PA-AM immunized mice versus 8 infiltrates in adju-
vant-immunized mice, these differences were not significant. However we did measure a signifi-
cant reduction in the percentage of diseased tissue (S7 Fig). AM-PA conjugate-immunized mice
lived longer than adjuvant-treated mice (median survival 337 days vs 297; log-rank P = 0.057,
GBW P = 0.049) and mice receiving BCG as a vaccine showed a survival mean time of 479 days
(p>0.001) (Fig 4D). These results suggest that immunity directed to AM can contribute to
reduced bacterial dissemination and lung inflammation, which in turn translated into prolonged
survival of infected mice.
AM-binding antibodies contribute to control bacterial dissemination
To establish that the protection observed following conjugate immunization was due to
humoral immunity we carried out a passive antibody transfer experiment using sera from
immunized mice. Mtb bacterial counts were enumerated in lungs and spleens 4 weeks
after challenge with a low dose of Mtb via aerosol (Fig 5A and 5B). We found that passive
administration of sera from Ag85b and AM-Ag85b-immunized mice was associated with
reduced bacterial CFUs in lung, as compared to adjuvant and naïve (PBS) mice (Fig 5A).
In mice that received AM-PA-immune serum, there was a significant reduction in lung
CFU of 0.4 log relative to PBS and adjuvant. Of note, although we observed a greater re-
duction in lung CFUs in mice that received Ag85b, this did not reach statistical signifi-
cance relative to mice transferred with PA-AM-serum. Consistent with the ability of AM-
PA and AM-Ag85b conjugates to control bacterial dissemination (Fig 4B), we observed
that sera from conjugate-immunized mice significantly reduced the bacterial CFUs in
spleen, with AM-Ag85b-immune serum being superior to AM-PA-immune serum (no
statistically significant differences, P = 0.054) (Fig 5B). We observed no benefit from the
transfer of serum from BCG immunized mice. These results strongly indicate that specific
antibodies to AM and Ag85b contribute to control bacterial dissemination. The greater
protective efficacy achieved by AM-Ag85b immune serum might be due to either syner-
gistic or additive effects of antibodies to these two antigens.
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Fig 5. Passive transfer of immune serum and adoptive T cell transfer modify the course of mycobacterial infection.
(A,B) Bacterial burden (CFUs) in the lungs (A) and spleen (B) at 4 weeks after infection with a low dose of Mtb H37Rv via
aerosol (approx. 100 CFUs) of individual naïve C57BL/6 mice that previously received passively serum preparations. Results
are representative of two similar and independent experiments. Experimental groups used 5 mice. (*P < 0.05, **P<0.01, one-
way ANOVA with Tukey post-test). (C,D) Bacterial load (CFUs) in the lungs (C) and spleen (D) of individual naïve C57BL/6
mice adoptively transferred with 4 x 106 T cells from the indicated immunized mice were determined at 4 weeks after infection
with a low dose of Mtb H37Rv via aerosol (approx. 100 CFUs). The results are representative of two similar and independent
experiments. Experimental groups used 5 mice. (*P < 0.05, **P<0.01, one-way ANOVA with Tukey post-test).
https://doi.org/10.1371/journal.ppat.1006250.g005
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T cells from AM-Ag85b mice mediate protection against M. tuberculosis
We next tested the ability of memory T cells from long-term immunized mice (S8 Fig) to pro-
tect naïve recipient mice against virulent Mtb by using a T-cell adoptive transfer protocol. Bac-
terial counts were enumerated in lungs and spleens 4 weeks after challenge with a low dose of
Mtb via aerosol (Fig 5C and 5D). Remarkably, mice transferred with T cells from AM-Ag85b
or Ag85b immunized mice showed significant reduction in CFU in the lung (Fig 5C) and
spleen (Fig 5D), relative to PBS and Alum-mice. Mice receiving AM-PA-specific T cells did
not show any capacity to control bacterial replication in lung and spleen (Fig 5C and 5D). The
transfer of T cells from Alum or BCG-vaccinated mice did not translate into any protection.
The later result is consistent with reports that transfer of BCG-induced immunity requires sub-
lethal irradiation of recipients [31]. These data strongly suggests that the superior protection
provided by AM-Ag85b conjugates is a combination of both AM and Ag85b-binding antibod-
ies and Ag85b-specific T cells.
Antigenic variability of capsular AM
Some encapsulated variants of many bacterial clinical isolates are associated with higher rates
of mortality and morbidity and consequently vaccine development is focused on the these ser-
ogroups [32]. Carbohydrate antigens exhibit tremendous structural variation that can translate
into antigenic variation as demonstrated by the 13 different serogroups of Neisseria meningiti-
dis, over 90 different serotypes in Streptococcus pneumoniae or the more than 80 serotypes in
Klebsiella sp [33]. However, for Mycobacterial spp. the question of polysaccharide-related anti-
genic differences on the bacterial surface has not been investigated. We hypothesized that AM
presents antigenic variability among Mtb isolates given that it is a variable structure compris-
ing a mannan backbone substituted by a branched arabinan, which is further modified by
mannose residues at the non-reducing end. To investigate AM antigenic variability we ana-
lyzed a panel of 17 strains, including Mtb H37Rv, representing the 6 known lineages of Mtb
strains globally distributed [34] and tested for AM and α-glucan reactivity to the 9d8 mAb
(AM) and 24c5 mAb (α-glucan), respectively (Fig 6). We could measure some statistically dif-
ferences in Ab recognition between isolates form the same lineage. However, we also could
establish some correlates. We observed that AM of isolates from L1, L5 and some from L3
showed the highest binding to 9d8 mAb. L6 showed the lowest binding with a reduction of an
80% relative to Mtb H37Rv. Isolates from L4 showed a 50% reduction in AM binding to 9d8.
Of note, we did not find as much variability in the binding of α-glucan to mAb among the dif-
ferent isolates. Most of the isolates showed a reduction in binding relative to Mtb H37Rv, in
the range of 50–60%. Only isolates from L4 and L5 showed a similar reactivity. These results
suggest that AM is the main source of antigenic variability in the mycobacterial capsule and
establish different antigenic groups among Mtb clinical isolates. However, we cannot rule out
that the relative distribution of capsular polysaccharides may be relevant for their binding to
specific Abs. To understand the antigenic variability contributed by AM would require a more
extensive analysis, including more Mtb isolates.
AM-conjugate specific serum is opsonic to unencapsulated bacteria
Standard protocols for murine infection with Mtb use inoculum as a homogeneous bacterial
suspension after growth in detergent. However, the generation of single cell suspensions using
detergent to avoid clumping also can remove the capsular layer [2, 35]. Indeed, a recent study
using Cryo-Electron microscopy (Cryo-EM) revealed that this layer is removed when cells are
grown in the presence of detergent or agitation [4]. Since AM is part of the capsule we rea-
soned that capsular polysaccharide conjugate vaccines may be even more effective when the
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capsule is present and were concerned whether the bacteria in the inoculum would bind anti-
body since these had been treated with detergent. To test whether there was antigen on the sur-
face of such cells we performed macrophage infections with Mtb previously opsonized with
conjugate (AM-PA) serum and a preimmune mouse serum. Bacterial counts were enumerated
2 h after infection (S9 Fig). The percentage of bacterial uptake by macrophage was significantly
higher when bacteria were previously treated with conjugate serum relative to an untreated
control or bacteria treated with a preimmune serum. Notably, we could measure a statistically
significant difference in the macrophage uptake of encapsulated Mtb relative to unencapsu-
lated Mtb. This result indicates that the conjugate-specific serum still retain the opsonic prop-
erties even though the capsule may have been removed, at least in part, by growth in media
with detergent.
Discussion
Here, we demonstrate that immunization with mycobacterial capsular arabinomannan (AM)
conjugates elicited responses that contribute to protection against Mtb infection. In this study
we, (i) isolated capsular AM from the H37Rv strain of Mtb and developed conjugates with the
Mtb related protein Ag85b and Mtb unrelated PA from B. anthracis; (ii) found that immuniza-
tion with different AM conjugates elicited antibody populations with different specificities;
Fig 6. Antigenic variability of AM among Mtb isolates. Relative reactivity of Mtb isolates representing 6 of known lineages. The binding is
shown as the percentage of reactivity compared to Mtb H37Rv. Data are mean +/- sem. Results are representative of two independent
experiments. (ns, non significant, *P < 0.05, **P<0.01, one-way ANOVA with Tukey post-test).
https://doi.org/10.1371/journal.ppat.1006250.g006
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(iii) showed that surface-specific antibodies could directly modify the transcriptional profile
and metabolism of mycobacteria; (iv) observed a prolonged survival and a reduction in bacte-
rial numbers in lungs and spleen in mice immunized with Ag85b-AM conjugates after infec-
tion with Mtb; (v) observed that the presence of AM-binding antibodies was associated with
modest prolongation in survival and a marked reduction in mycobacterial dissemination; (vi)
and demonstrated that AM is antigenically variable and could potentially form the basis for a
serological characterization of mycobacteria based on serotypes.
Our conjugates generated antibodies to cell-surface AM and LAM, given the overlapping
structural motifs in these glycoconjugates. It is noteworthy that the vaccinated mice were chal-
lenged with bacteria grown in the presence of detergent, a condition that strips the mycobacte-
rial polysaccharide capsule [22], and thus reduces AM epitopes. Consequently, the efficacy of
these conjugates may be greater against encapsulated bacteria.
To our knowledge, this study represents the first effort to investigate a native mycobacterial
capsular polysaccharide in a vaccine against pulmonary Mtb infection. Prior studies evaluating
AM antigens in experimental conjugate vaccines have used either secreted AM [16] or delipi-
dated LAM [15]. In the former report, mice were immunized with extracellular AM conjugates
including the recombinant Pseudomonas aeruginosa exoprotein A (rEPA), with no adjuvant,
and challenged intravenously with M. tuberculosis Erdman. A moderate reduction in lung CFU
was observed early in the course of infection [16]. In the latter, AM oligosaccharides (AMOs)
derived from LAM of Mtb H37Rv were isolated and covalently conjugated to tetanus toxoid
(TT) or to Ag85b from Mtb. Ag85b conjugates were given to mice in Alum providing significant
protection compared to sham immunized mice as estimated by long term survival against an
intravenous challenge Mtb H37Rv [15]. AMOs-TT conjugates were given subcutaneously fol-
lowed by nasal boost in the Eurocine L3 adjuvant providing a similar level of protection after a
similar challenge with virulent M. tuberculosis. Remarkably, the protective efficacy was compara-
ble to that of BCG vaccine. In guinea pigs, immunization with AMOs-Ag85b in Eurocine L3
adjuvant followed by an aerosol challenge with Mtb H37Rv showed an increased in survival and
reduced pathology in lungs and spleens relative to non-immunized animals [15]. It is difficult to
compare the efficacy of these vaccines as each was tested using different conditions that included
the route of immunization, mode of infective challenge or animal model. In fact, only the study
using AMOs-Ag85b immunization followed by an aerosol challenge [15] can be compared to
our study even though it differs in the mouse strain used as experimental host. Nevertheless,
each of these studies provide the consistent result that antibodies to AM modified the course of
Mtb infection to the benefit of the host.
Animals immunized with the AM-Ag85b conjugate lived significantly longer than Ag85b-
immunized mice, indicating that AM-specific immunity contributes to the protection. Also,
we found a similar reduction in CFUs between AM-Ag85b conjugate- and Ag85b-immunized
mice. Because Ag85b is a highly immunogenic antigen from Mtb that can elicit protective
responses, it is difficult to assess the contribution of AM-specific immunity to the overall pro-
tection. Consequently, we also developed AM conjugates including the Mtb unrelated protein
PA to study the specific contribution of antibodies to AM to the overall protection and found
that circulating antibodies against AM reduced mycobacterial extrapulmonary dissemination
in mice, as significant fewer CFUs were detected in spleens. Moreover, mice immunized with
AM-PA conjugates manifested only a modest prolongation in survival compared to adjuvant-
immunized mice. That the effect on CFU was antibody mediated was confirmed by passively
transferring AM-specific serum to naïve mice and showing a similar reduction in CFUs in
spleen after infection.
Considering that only zwtterionic polysaccharides can elicit T cell responses [36] and that
AM is a neutral polysaccharide, it is extremely unlikely that a polysaccharide-specific T cell
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response was responsible for the protective efficacy of the AM-PA conjugate. This fact is con-
sistent with the finding that the transfer of AM-PA T cells does not confer any protection. We
observed a trend to a superior protection of AM-Ag85b T cells relative to Ag85b-T cells.
Although we do not have a clear explanation for this result we cannot rule out the possibility
that the covalent conjugation of AM to Ag85b altered the processing of T cell epitopes in
Ag85b to elicit enhanced T cell responses that could be translated into a better protection. A
precedent for such an effect was reported in pneumococcal polysaccharide-protein conjugates
where the type of polysaccharide altered the T cell response to protein epitopes [37]. Further-
more, conjugation of a PstS1 synthetic peptide to a branched polysaccharide, including a poly-
lysine backbone and DL-alanine side chains elongated by glutamic acid, enhanced human T
cell proliferation to peptide [38]. Cross-protection form heterologous unrelated antigen (heter-
ologous immunity) has been reported in viral infection [39]. Experiments addressing the qual-
ity of Ag85b-specific responses, possibly involving tetramer analysis, will be of paramount
importance to gain insight into this finding.
Our findings are consistent with and supportive of the view that antibodies can play a sig-
nificant role in the overall protection against Mtb. In addition to the effects observed with anti-
bodies to AM, we obtained evidence that Ag85b-specific antibodies contributed to the control
of bacterial replication in lung and spleen as demonstrated by passive transfer experiments.
The fact that bacterial numbers in spleens of mice transferred with AM-Ag85b-specific serum
were lower relative to mice transferred with Ag85b-specific serum or AM-PA-specific serum,
suggests a synergistic effect of antibodies to both the mycobacterial polysaccharide and protein
conjugate components. It is noteworthy that Ag85b immunization was previously shown to
induce protective responses against Mtb that were believed to be dependent only on cell-medi-
ated immunity [40–44]. Our observations suggest that humoral responses to Ag85b could have
also contributed to protection in those vaccine studies.
The specificity of antibodies elicited by AM conjugates was characterized using an array
including a set of 30 fragments representing the AM molecule. The AM glycan microarray
revealed an enhanced and more diverse response in mice immunized with Mtb AM conjugates
than the AM-specific mAb 9d8. Surprisingly, the most reactive fragments included non-manno-
sylated arabinnan structures with variable grades of branching, indicating that the glycosydic
determinant of AM antigenicity is the arabinnan and not mannose part. We observed weak
binding of pooled sera from PA and Ag85b-immunized mice to some fragments. Although this
binding was low and close to the limit of detection, we cannot rule out that these antigens elicited
some weak cross-reactive antibody responses. The fact that AM might be antigenically variable
suggests that the abundance or the features of this polysaccharide may be different from strain to
strain. In fact, our finding that the reactivity of AM containing sera differed from strain to strain
suggests a previously unknown antigenic variation at the mycobacterial surface. This result
could have very important implications for vaccine design because it suggests the possibility that
some of the variability of BCG and live vaccine candidates may have been the result of antigenic
differences between immunizing and infecting strains. Furthermore, this antigenic variation
implies that any vaccine attempting to target mycobacterial polysaccharides should include cock-
tails of polysaccharide or oligosaccharides to cover likely epitopes. In fact, such an approach has
proven very successful in vaccination against pneumococcus.
Incubation of AM with mycobacteria resulted in altered metabolism of Mtb implying a
direct effect of antibody on bacterial cells. This phenomenon was previously reported with
fungi [24] and Gram positive bacteria [25] and is now extended here to mycobacteria. Upregu-
lation of almost the entire mce1 operon upon AM-specific antibody indicates a very specific
response to immunoglobulin binding on the surface. This operon is highly induced when Mtb
is inside the host and a mce1 mutant has more intracellular fatty acids, including mycolic acids
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[26, 27]. We found that upon upregulation of mce1 operon, Mtb reduces the synthesis of
mycolic acids. This finding raises the possibility that Mtb may become more susceptible to
macrophages after interaction with AM-binding antibodies since mycolic acids strongly con-
tribute to Mtb cell wall permeability and rigidity. The ability of AM-binding antibodies to
modify Mtb metabolism opens a new door in our understanding of the potential of humoral
immunity against mycobacteria. In addition, we have recently demonstrated that increased
human serum IgG titers to capsular AM were associated with enhanced mycobacterial opsono-
phagocytosis, increased phagolysosomal fusion and intracellular growth reduction in human
macrophages; data suggesting that these effects of antibodies to AM are FcR-mediated [45].
We thus hypothesize that some of the effects of the Abs induced by the AM conjugate vaccine
are FcR-mediated, while some of the Mtb transcriptional changes could reflect a more direct
growth reducing effect on Mtb. Functional in vitro and in vivo studies with monoclonal Abs
are needed to further elucidate the specific effects by which Abs to AM and its oligosaccharide
epitopes contribute to the defense against Mtb infection.
Vaccine design in the TB field has been driven by the imperative of attempting to elicit
strong cell-mediated responsive while disregarding humoral immunity against Mtb. This view
was fueled by overwhelming evidence for an important role for cell-mediated immunity while
the role for humoral immunity was considered inconsistent at best. Further fueling this
emphasis was the notion that since Mtb is an intracellular pathogen, immunoglobulins as
extracellular molecules cannot reach this pathogen. However, that two-dimensional view has
been supplanted by the realization that humoral immunity can protect against many intracel-
lular pathogens through numerous mechanisms [46, 47]. Moreover, recent studies have shown
that immunoglobulins can have direct effects on microbes including triggering signal trans-
duction and modulating their physiology [48]. The difficulty of assigning a functional role for
Abs against Mtb was recently uncovered as being due to the heterogeneity of the Ab response
[49]. In addition, human Mtb-specific IgAs have superior capacity to inhibit Mtb growth than
IgG antibodies [50], indicating that mucosal immunity should be highly considered. In this
regard, we could not measure AM and Ag85b-specific IgAs in serum and BALs, suggesting
that the lack of protection provided by the PA-AM conjugate in the lung might be due to the
absence of this Isotype.
Although the mechanism of action of antibodies to AM has not been determined,
there are a number of possibilities by which these antibodies can mediate protection
based on precedents from other systems. AM-binding antibodies could: (i) promote the
ingestion by phagocytic cells and increased intracellular killing through FcR-mediated
phagocytosis [45, 51]; (ii) alter the inflammatory response thus reducing host-damaging
effects on the immune response [52]; iii) promote the clearance of polysaccharide anti-
gens from tissues thus removing immunomodulatory antigens with deleterious effects on
the immune response; and/or iv) modulate the metabolism of Mtb to make it more sus-
ceptible to host defense mechanisms [53]. Vaccines that elicit AM-binding antibodies
may have the potential to recruit humoral immunity for host defense, which could
achieve synergy with cellular immune mechanisms.
In summary, our findings are consistent with role of AM-binding antibodies in defense
against Mtb infection and suggest that vaccines that elicit both humoral and cell-mediated
immunity may be more protective than those that elicit either. These data suggest that anti-
body-mediated immunity can make an important contribution to the outcome of mycobacte-
rial infection and provide a new impetus for developing vaccines that harness this arm of the
immune system.
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Methods
Strains and reagents
M. bovis BCG Pasteur and Mtb H37Rv were grown in minimal medium (MM) [KH2PO4 1 g/l,
Na2HPO4 2.5 g/l, asparagine 0.5 g/l, ferric ammonium citrate 50 mg/l, MgSO4×7 H2O 0.5 g/l,
CaCl2 0.5 mg/l, ZnSO4 0.1 mg/l, 0.1% (v/v) glycerol, and with or without Tyloxapol 0.05% (v/v;
Sigma), pH 7.0] or in Middlebrook 7H9 supplemented with 10% (v/v) OADC enrichment (Bec-
ton Dickinson Microbiology Systems, Spark, MD), 0.5% (v/v) glycerol and with or without
Tyloxapol 0.05% (v/v) for 14 days in a 5% CO2 incubator at 37˚C. Mtb lineages were a gift from
Sebastien Gagneux. Mtb lineages were systematically grown in MM supplemented with 30 mM
pyruvate.
Recombinant Ag85b was obtained from AERAS Tb vaccine Foundation (Rockville, MD).
Recombinant PA (Protective Antigen from Bacillus anthracis) was obtained from David Axel-
rod Institute, Albany, NY). The 1-cyano-4-dimethylaminopyridinium tetrafluoroborate
(CDAP) and the other reagents used during the conjugation reaction were purchased from
Sigma. The CS-35 monoclonal antibody recognizing LAM and AM, was obtained from BEI
resources (Manassas, VA). The monoclonal antibody 9d8 specifically recognizes mycobacterial
capsular AM [10, 54]. The monoclonal antibody 24c5 specifically recognizes mycobacterial
capsular α-glucan [55]. Alhydrogel was purchased from InvivoGen (San Diego, US).
Polysaccharide isolation
Capsular polysaccharides were isolated as described, with some modifications [5, 18]. Briefly,
cells were pelleted from cultures at 3,450 x g for 15 min at 4˚C. Five mg of glass beads (4 mm,
Fisher) per g of cells were added and the mixture was gently shaken by vortex for 1 min. A vol-
ume of 50 ml of distilled water was added per g of disrupted cells and centrifuged at 8000 x g
for 10 min at 4˚C. The supernatant was recovered, clarified in a 0.22 μm filter unit (Millipore)
and lyophilized. To separate the capsular arabinomannan (AM) from the rest of capsular poly-
saccharides, the capsule residue was resuspended in 4 ml of distilled water and subjected to a
chloroform:methanol:water extraction (1:1:0.9). The upper phase was recovered and incubated
in a rotavapor at 40˚C overnight. Proteinase K (Sigma) was added at 10 mg/ml in a 50 mM
Tris-HCl pH 7.5, 10 mM CaCl2 buffer and incubated overnight at 37˚C. The deproteinated
solution was dialyzed for 3 d at 4˚C in distilled water, lyophilized and chromatographed on a
column (90 cm x 1.8 cm) of Bio-Gel P-10 (Bio-Rad) using 0.1 M NaCl in 0.1% acetic acid. Col-
lected fractions of 4 ml were assayed for carbohydrate content by the phenol-sulfuric acid
assay. Pooled fractions were dialyzed in water and lyophilized. The concentration of protein
was determined on each isolation step by Bradford.
Conjugates
Mycobacterial AM-PA and AM-Ag85b conjugates were prepared as described [19, 56]. Briefly,
6 mg of AM was dissolved in 1 ml of borate buffer pH 9.0 and 60 μl of 100 mg/ml 1-cyano-
4-dimethylaminopyridinium tetrafluoroborate (CDAP) was added and mixed with agitation
for 10 min at room temperature. Then 6 mg of recombinant PA or Ag85b was added in 0.5 ml
of 0.15 M HEPES pH 7.5, and the mixture was incubated for 1 h. The reaction was stopped
with 100 μl of 0.15 M ethanolamine and incubated for 1 h. The mixture was then dialyzed in
PBS for 2 days. To isolate the conjugates from the non-bound AM and PA or Ag85b, the dia-
lyzed conjugated reaction was separated by FPLC on a Sephacryl SH200 (GE Healthcare) in
PBS. Each fraction was then assayed for polysaccharide and protein content by the phenol-sul-
furic acid assay and Bradford assay, respectively.
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Immunization
C57BL/6 female mice between 6 to 8 weeks old were purchased from Jackson Laboratories
(Bar Harbor, MN). Animals were maintained in a specific pathogen-free animal facility under
animal biosafety level-2 conditions for all experiments except for those involving infection
with virulent Mtb for which animal biosafety level-3 conditions were used. Animals were
immunized intraperitoneally (i.p) three times with 10 μg of Ag85b-AM or PA-AM conjugates
including 1% (w/v) Alum, 1 μg of Ag85b or PA alone including 1% (w/v) Alum. Immuniza-
tions were given every two weeks. Control mice received i.p. injections of PBS or 10 μg of AM
including 1(w/v) Alum. Alternatively, mice were vaccinated subcutaneously with 1 million
BCG as a positive control in protection efficacy experiments or survival studies.
Murine infections
Aerogenic challenge was done using a whole-body exposure aerosol chamber (Mechanical
Engineering Workshop) custom fitted to a class III biosafety cabinet (Baker) to deliver approx-
imately 100 CFU per animal of Mtb (H37Rv). Immunized mice were infected four weeks after
the last immunization and eight weeks after BCG immunization. Mice were euthanized at 15
and 30 d after challenge. Lungs of individual mice were aseptically removed and homogenized
separately in 5 ml normal saline plus 0.05% Tyloxapol using a Seward Stomacher 80 blender
(Tekmar). The homogenates were diluted serially and plated on Middlebrook 7H11 agar to
determine CFU of Mtb. Dilutions 10−2 and 10−3, and 10−2 and 10−1 were platted when count-
ing CFUs in lungs and spleens, respectively.
In bacterial loads studies, animals infected with Mtb H37Rv were observed at least twice
daily until they died or became moribund and were euthanized.
Macrophage infection
J774 macrophages (ATCC TIB 67) were plated in 96-well plates in complete DMEM. The cells
were washed with DMEM and infected with Mtb, previously grown in MM with or without
Tyloxapol, at an MOI of 10:1 for 2 h at 37˚C. Before infection bacteria were opsonized with
20 μg/ml of pre-immune serum or H37Rv-conjugate serum for 30 min. Cell lysates were pre-
pared by removing the medium and lysing with 0.05% SDS. Serial dilutions of the lysate were
plated on 7H11 agar, and incubated at 37˚C for 21 days before counting CFUs.
Transmission electron microscopy
Cells of M. bovis BCG Pasteur and M. tuberculosis H37Rv were grown in minimal medium
and fixed with 2% glutaraldehyde in 0.1 M cacodylate at room temperature for 2 h, and then
incubated overnight in 4% formaldehyde, 1% glutaraldehyde, and 0.1% PBS. After fixation the
samples were stained for 90 min in 2% osmium tetraoxide, then serially dehydrated in ethanol
and embedded in Spurrs epoxy resin. Thin sections were obtained on an Ultracut UCT (Reich-
ert) and stained with 0.5% uranyl acetate and 0.5% lead citrate (Reichart, Depew, NY, USA).
Immunogold TEM (IEM) was performed as previously described with a polyclonal murine
immune serum diluted 1:300 or monoclonal murine IgG2a 9d8 antibody (10 μg ml-1) and
then immunogold stained using 6 nm goat α-mouse gold (Electron Microscopy Sciences).
Samples were viewed on a JEOL 100CXII or JEOL 1200EX at 80kV.
Scanning electron microscopy
Cells of M . bovis BCG Pasteur and M. tuberculosis H37Rv were fixed with 2.5% glutaraldehyde,
0.1 M sodium cacodylate, 0.2 M sucrose, 5 mM MgCl2 pH 7.4 and dehydrated through a
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graded series of ethanol solutions. Critical point dry was accessed using liquid carbon dioxide
in a Toumisis Samdri 795 Critical Point drier (Rockville,MD, USA). Sputter was coated with
gold-palladium in a Denton Vacuum Desk-2 Sputter Coater (Cherry Hill, NJ, USA). Samples
were examined in a Zeiss Supra Field Emission Scanning Electron Microscope (Carl Zeiss
Microscopy, LLC North America), using an accelerating voltage of 5 kV.
ELISA
Two types of ELISA were used in this study. In one assay polystyrene microtiter plate wells
were coated with 50 μl of AM (5 μg/ml) in carbonate buffer (0.015 M Na2CO3, 0.035 M
NaHCO3, 0.003 M NaN3; pH 9.8) or with 1 μg of recombinant proteins (PA or Ag85b) in PBS
by incubating the plates 2 h at room temperature. The wells were then blocked by adding
200 μl of 2% BSA in TBS and incubated at 37˚C for 1 h. Serum from conjugate-immunized
mice, PBS-injected mice or recombinant Ag85b or PA-injected mice were added to the wells
and incubated for 1 h at 37˚C. The plates were then washed and 50 μl of a 1 μg/ml solution of
Goat anti-mouse-alkaline phosphatase (GAM-AP) IgG1, IgG2b, IgG2c, IgG3 or IgM antibody
(Southern Biotechnologies) for 1 h at 37˚C. The ELISA plates were washed and developed by
using p-nitrophenylphosphate substrate. Results are presented as inverse titers, what means
the inverse of the greatest dilution that still gives a positive result, after removing the back-
ground (2 times OD from control serum). Isolated AM from KZN clinical isolates was also
tested for reactivity to mAb 9d8 and AM-immune serum following the above protocol.
Whole cell ELISA was used to measure the relative reactivity of monoclonals Ab 9d8
and 24c5 to different clinical isolates. For this ELISA, mycobacterial cells were killed by
heating to 80˚C for 2 h. Bacterial cells were dispersed by drawing up and expelling the bac-
terial suspension 10 times through a 25-gauge needle attached to a 1-ml syringe. The sus-
pension was then allowed to settle in a transparent 1.5-ml microcentrifuge tube, and the
supernatant was removed, leaving 100 μl of settled bacteria. The number of bacteria used was
standardized according to the amount of protein in a 100-μl volume of sedimented bacteria.
Coated plates were blocked as above and incubated with either a-glucan-specific mAb 24c5
or AM-specific mAb 9d8. The plates were then washed and 50 μl of a 1 μg/ml solution of goat
anti-mouse-alkaline phosphatase (GAM-AP) IgG antibody was added to each well for 1 h
at 37˚C. The ELISA plates were washed and developed by using p-nitrophenylphosphate
substrate.
AM microarray
A panel of 30 AM fragments (corresponding to motifs at the non-reducing terminus of the
molecule, which have previously been shown to be recognized by anti-AM/LAM Abs) [57–59]
were synthesized, and coupled to BSA via a squarate-linker [60]. Arrays were printed and used
as described [61]. Briefly, after blocking with 3% BSA/PBS, AM microarrays were incubated
with diluted mouse sera (1:400), or the murine IgG2a mAb 9d8 (known to recognize only Mtb
AM) [62], followed by incubation with goat anti-mouse biotin-labeled IgG (Southern Biotech,
AL; Jackson Immunoresearch, PA) and incubation with a Streptavidin probe tagged with Sure-
Light-P3 Cy5 (Cayman Chemicals, MI). The slides were scanned using the GenePix 4000
Microarray scanner system (Molecular Devices, CA). Images were analyzed by the image-pro-
cessing software Spotfinder (http://www.tm4.org/spotfinder.html), which measured median
pixel intensity (MPI) and neighboring background pixel intensity (BPI) of individual spots.
The median fluorescent reactivity (MFI), representing AM-epitope specific Ab responses, was
the MPI subtracted by the BPI. The minimum value of pixel intensity was determined by the
MFI of the spots with low quality, which was determined by the software quality control score
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for each spot depending on signal-to-noise ratio and spot shape. The final MFI was averaged
from the triplicates. The symbolic nomenclature used is that recommended by the Consortium
for Functional Glycomics. Green circles = mannose; Green stars = arabinose; orange stars =
5-thiomethyl-xylose; white ovals = inositol. The linkage position and stereochemistry between
the monosaccharides is indicated over the line connecting them. 3P5 = a phosphate linkage
between O3 of the inositol and O5 of an arabinose residue [63].
Microarray analysis
M. tuberculosis was grown in MM with detergent for 6 days and then subcultured in fresh MM
without detergent for 5 days. Cultures were harvested and submitted to a syringe and gentle
sonication to breakdown the clumps. Bacterial cells were further incubated with AM-PA and
PA immune sera (1:200 dilution) for 4 h. After treatment cell were washed once on PBS and
resuspended in Trizol (Ambion, Carlsbad, CA). Cells were disrupted by mechanical lysis in a
FastPrep-24 instrument (MP Biomedicals, Santa Ana, CA) in Lysing Matrix B tubes and RNA
was purified with the Direct-zol RNA miniprep kit (Zymo Research, Irvine, CA). cDNA
probes were prepared and hybridized to DNA microarrays (Microarrays, Inc. Huntsville, AL),
which were scanned and analyzed as described previously [64]. Briefly, slides were scanned on
a GenePix 4000A scanner (Molecular Devices, Sunnyvale, CA) and processed with the TM4
software suite (http://www.TM4.org). TIGR Spotfinder was used to grid and quantify spots.
TIGR MIDAS was used for Lowess normalization, standard deviation regularization and in-
slide replicate analysis, with all quality control flags on and one bad channel tolerance policy
set to generous. Results were analysed in MeV with Significance Analysis of Microarrays
(SAM) and hierarchical clustering algorithms. Microarray data was deposited with the GEO
NCBI database with the accession number GSE77711.
For quantitative PCR (qPCR) experiments, diluted cDNA was used as a template at 50 ng
per reaction for real-time PCR reactions containing primer sets designed by Primer 3 and
SYBR Green PCR Master Mix (Applied Biosystems) in accordance with the manufacturers’
instructions. qRT-PCR reactions were performed on an ABI 9700HT real-time PCR cycler
(Applied Biosystems).
Fatty acid analysis
M. tuberculosis was grown in MM with detergent for 6 days and then subcultured in fresh MM
without detergent for 5 days. Cultures were harvested and submitted to a syringe and gentle
sonication to breakdown the clumps. Bacterial cells were further labeled with 14C-acetate
(10μCi in 10ml culture) for 22h and incubated with AM-PA and PA immune sera (1:400 dilu-
tion) for 10 h. Bacterial pellets were treated with 20% tetrabutylammonium hydroxide at
100˚C overnight. Cell suspensions were further methylated with methyl iodide (0.1ml) in
dichloromethane (2ml) for 1h and the organic phase was washed twice and dried [65]. Fatty
acids were analyzed by TLC (hexane/ethyl acetate; 95/5; 3 elutions).
Histology
Lungs were removed and fixed in 10% neutral buffered formalin (Fisher Scientific, Fair Lawn,
NJ). Tissues were embedded with paraffin, sectioned at 5 μm thickness, and stained with hae-
matoxylin and eosin stain. Five different lung sections per mouse were analyzed. Slides were
scanned with a Perkin Elmer P250 High Capacity Slide Scanner (Waltham, Massachusetts) at
2,000 dots per inch (dpi). Digitized images were then analyzed using ImageJ software to calcu-
late the total disease area occupied by granuloma and the percentage of lung surface affected
by pneumonia as well as the number of infiltrates per lung. The total disease area for the entire
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lung section was calculated by adding the values for each lesion. The total percentage of dis-
eased tissue was calculated by dividing the total disease area by the entire lung section and
multiplying by 100, using image J software.
Passive serum transfer experiments
Blood was collected from the retro-orbital plexus from C57BL/6 mice immunized three times
with either 10 μg of Ag85b-AM conjugate, 1 μg of Ag85b, 10 μg of PA-AM conjugate, 1 μg of
PA in 200 μl of 1% (w/v) Alum. Vaccines were administered at two weeks intervals. Control
sera were obtained from mice that received i.p. injections of PBS, 1% (w/v) Alum or 1 million
of bacteria of BCG (subcutaneously). Sera were collected after clarification by centrifugation of
clotted blood and stored at −80˚C until use. Two hundred μl of immune and control sera were
administered i.p. 4h before infection with 100 CFU of M. tuberculosis H37Rv. Four weeks after
infection mice CFUs were assessed in lung and spleen.
Adoptive T cell transfer experiments
Total T cell populations were isolated from spleens from C57BL/6 mice immunized three times
with 10 μg of Ag85b-AM conjugate, 1 μg of Ag85b, 10 μg of PA-AM conjugate, 1 μg of PA in
200 μl of 1% (w/v) Alum. Control T cells were obtained from mice that received i.p. injections of
PBS, 1% (w/v) Alum or 1 million of bacteria of BCG (subcutaneously). Spleens were homogenized
and treated with RBC lysis buffer (Sigma–Aldrich, St. Louis, MO). Splenic T cells were purified
using the Pan T cell isolation kit (Miltenyi Biotec, Germany). An aliquot of isolated T cells was
stimulated with 1 μg ml−1 of the synthetic peptide antigens (Invitrogen): FQDAYNAAGGH-
NAVF (Ag85B-P25; residues 240–254 of MTb/BCG Ag85B, I-Ab restricted); and 5 μg ml-1 of PA
from Bacilllus anthracis to assess their specificity. Unstimulated wells served as negative controls
in naive mice. Samples were combined with 1 μg ml−1 soluble antibody to mouse CD28 (clone
37.51; eBioscience) and 1 μg ml−1 soluble antibody to mouse CD49d (clone 9F10; eBioscience).
After 2 h at 37˚C, 10 μg ml−1 of brefeldin A (Sigma) 10 μg ml−1 of monensin (Sigma) were added
to all samples, followed by incubation for 6 h at 37˚C. Cells were stained with blue LIVE/DEAD
viability dye (Invitrogen) followed by antibody to FcγRII/III (clone 2.4G2; American Type Cul-
ture Collection), with fluorochrome-conjugated monoclonal antibodies for surface staining: anti-
body to CD3ε (clone 145-2C11; eBioscience), antibody to CD8α (clone 53–6.7; BD Bioscience),
antibody to CD4 (clone GK1.5; BD Bioscience), and antibody to CD45R (B220) (clone RA3-6B2;
BD Bioscience). Cells were fixed with 2% (vol/vol) paraformaldehyde, washed with permeabiliza-
tion buffer (PBS with 1 mM Ca2+, 1 mM Mg2+, 1 mM HEPES [N-2-hydroxyethylpiperazine-N0-
2-ethanesulfonic acid], 2% [vol/vol] FCS, and 0.1% [wt/vol] saponin) and then blocked in per-
meabilization buffer plus 5% (vol/vol) normal mouse serum (Jackson ImmunoResearch Labora-
tories). Intracellular cytokines were detected with fluorochrome-conjugated antibodies to IL-2
(clone JES6-5H4; eBioscience), IFN-γ (clone XMG1.2), TNF-α (MP6-XT22) (both from BD Bio-
sciences). Data were acquired on an LSR II flow cytometer (BD Biosciences), and data analysis
was performed using FlowJo software v.10 (Tree Star).
C57BL/6 mice were injected i.p with 4 mg/mouse of cyclophosphamide to partially deplete
lymphocytes and promote engraftment of transferred cells [66], and 2 days later received adop-
tive transfer of 4 × 106 isolated total T cells. Twenty-four h later the recipient mice were sub-
jected to a low dose (50–100 CFU) aerosol challenge with Mtb H37Rv. Lungs and spleens were
harvested for CFU counts 4 weeks after infection.
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Statistical analysis
Standard one-way ANOVA followed by Tukey’s multiple comparison test of the means was
used to determine statistical significance of immune responses and protective efficacies of the
conjugates. P<0.05 was considered statistically significant.
Survival data were analyzed by comparing Kaplan-Meier survival curves with a log-rank
test (GraphPad Prism); after the log-rank test, a Grehan-Breslow-Wilcoxon modification of
the log-rank test was used in an exploratory manner to apply more weight to early events in
experiments where larger differences in early survival were observed.
Ethics statement
Mouse studies were performed in accordance to National Institutes of Health guidelines using
recommendations in the Guide for the Care and Use of Laboratory Animals. The protocols
used in this study were approved by the Institutional Animal Care and Use Committee of
Albert Einstein College of Medicine (Protocols #20120110; #20150110).
Supporting information
S1 Fig. Isolation of capsular AM. (A) Electron micrograph of Mtb H37Rv cells grown in min-
imal media without detergent. Notice the capsule surrounding the cells. Scale bar is 100 nm.
(B) Scanning electron micrograph of Mtb H37Rv cells grown in minimal media without deter-
gent. Arrow denotes the polysaccharide capsule. Scale bar 1 μm. (C) Gel chromatography of
light Mtb capsular polysaccharides on a PD-10 size exclusion column. Fractions of 4 ml were
taken and the carbohydrate content was estimated by phenol-sulphuric acid method. “Vo”
means void volume. The pooled fractions are indicated by letters. (D) Binding of 9d8 (anti-
AM) (top graph) and 24c5 (anti-α-glucan) (bottom graph) monoclonal antibodies at various
concentrations of the indicated PD-10 fractions. The diagram indicates the ELISA configura-
tion. PS, Polysaccharide fraction; AP, alkaline phosphatase; GAM, goat anti-mouse. Capsular
polysaccharide isolation was performed up to four times using the same experimental condi-
tions. The results are representative of three independent experiments.
(PDF)
S2 Fig. Purification of AM-conjugates. (A,B) Separation of the conjugate reactions AM-Ag85b
(A) or AM-PA (B) on Sephacryl S-200 size exclusion column in PBS. Fractions were monitored
by on-line measurements of protein content at 280 nm (dotted line) and post-column by mea-
surement of carbohydrate content (straight line) by phenol sulphuric acid method.
(PDF)
S3 Fig. Kinetics of AM-binding antibodies after immunization with AM-Ag85b conjugates.
Inverse titers (total IgG) of AM-binding antibodies measured by ELISA in serum from C57BL/
6 mice (n = 3 per group) immunized with different amounts of AM-Ag85b conjugate. Mice
were immunized every two weeks twice after initial immunization. Measurements were per-
formed at 2, 4 and 8 weeks after the initial immunization.
(PDF)
S4 Fig. Specificity of AM-immune serum. Inverse titers of Abs from AM-Ag85b conjugate
serum for binding to different components of mycobacterial cell surface measured by ELISA in
serum from C57BL/6 mice (n = 3 per group). Mice were immunized three times with 10 μg of
AM-Ag85b conjugate. The results are representative of three independent experiments performed
in the same manner. AM, arabinomannan; AG, arabinogalactan; LAM, lipoarabinomannan; LM,
lipomannan; ManLAM, mannose capped LAM; TDM, trehalose deoxy mycolate; mAGP,
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mycolate arabinogalactan peptidoglycan. complex
(PDF)
S5 Fig. Immunogold electron microscopy of thin sections of Mtb H37Rv cells treated with
immune sera specific for the indicated antigens and detected with a 6-nm IgG gold-labeled
anti-mouse antibody. Mtb cells were grown in the presence (MMT) or in the absence of deter-
gent (MM). Scale bar 100 nm.
(PDF)
S6 Fig. AM fragments included in the glycan microarray representing the AM molecule.
The symbolic nomenclature used is that recommended by the Consortium for Functional Gly-
comics. Green circles = mannose; Green stars = arabinose; orange stars = 5-thiomethyl-xylose;
white ovals = inositol. The linkage position and stereochemistry between the monosaccharides
is indicated over the line connecting them. 3P5 = a phosphate linkage between O3 of the inosi-
tol and O5 of an arabinose residue [63].
(PDF)
S7 Fig. Morphometric analysis of lung histopathology by assessing the number of infiltrates
per lung (bottom graph) and the percentage of diseased tissue (top graph) (P< 0.05,
P<0.01 P< 0.001, one-way ANOVA with Tukey post-test); ns, not significant.
(PDF)
S8 Fig. Specificity of the isolated T cells. Mice were immunized with AM conjugates, PA and
Ag85b in Alum and after 4 weeks T cells were isolated. Specificity of CD4+ T cells was assessed
by intracellular cytokine staining after stimulation with the indicated antigens (PA, p25). Data
are mean +/- sem. Results are representative of two independent experiments.
(PDF)
S9 Fig. Phagocytosis of opsonized Mtb by J774 macrophages. J774 macrophages were
infected with unencapsulated (uncap) or encapsulated (encap) M. tuberculosis H37Rv, which
were previously opsonized with conjugate (H37Rv) serum (CS), pre-immune mouse serum or
untreated at an MOI of 10:1, and CFU counts were obtained 2 h after infection. Data shown
are representative of 2 independent and similar experiments (p< 0.05).
(PDF)
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